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Attractive therapeutic strategies to enhance post-stroke recovery of aged brains include
methods of cellular therapy that can enhance the endogenous restorative mechanisms of
the injured brain. Since stroke afflicts mostly the elderly, it is highly desirable to test the
efficacy of cell therapy in the microenvironment of aged brains that is generally refractory
to regeneration. In particular, stem cells from the bone marrow allow an autologous trans-
plantation approach that can be translated in the near future to the clinical practice. Such
a bone marrow-derived therapy includes the grafting of stem cells as well as the delayed
induction of endogenous stem cell mobilization and homing by the stem cell mobilizer
granulocyte colony-stimulating factor (G-CSF). We tested the hypothesis that grafting of
bone marrow-derived pre-differentiated mesenchymal cells (BM-MSCs) in G-CSF-treated
animals improves the long-term functional outcome in aged rodents. To this end, G-CSF
alone (50µg/kg) or in combination with a single dose (106 cells) of rat BM MSCs was admin-
istered intravenously to Sprague-Dawley rats at 6 h after transient occlusion (90 min) of the
middle cerebral artery. Infarct volume was measured by magnetic resonance imaging at
3 and 48 days post-stroke and additionally by immunhistochemistry at day 56. Functional
recovery was tested during the entire post-stroke survival period of 56 days. Daily treat-
ment for post-stroke aged rats with G-CSF led to a robust and consistent improvement
of neurological function after 28 days. The combination therapy also led to robust angio-
genesis in the formerly infarct core and beyond in the “islet of regeneration.” However,
G-CSF+BM MSCs may not impact at all on the spatial reference-memory task or infarct
volume and therefore did not further improve the post-stroke recovery.We suggest that in a
real clinical practice involving older post-stroke patients, successful regenerative therapies
would have to be carried out for a much longer time.
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INTRODUCTION
Stroke is a heavily undertreated disease demanding a vigorous
search for new therapies. Attractive therapeutic strategies stimu-
lating and finally enhancing the natural post-stroke regeneration
process include methods of training such as physio- or rehabili-
tative therapy or methods of cellular therapy (Liepert et al., 2004;
Hermann and Chopp, 2012; Honmou et al., 2012).
Studies of stroke have demonstrated an age and gender effects
on incidence, functional recovery and mortality, not only in
humans but also in animal models (Bergerat et al., 2011; Gok-
cay et al., 2011). Therefore, studies on physiologically complex
organisms like rats, mice, or non-human primates are required to
investigate the molecular mechanisms of aging in humans or to
predict human responses to age-related diseases or the response
of aged organisms to drugs. The aged rodent model offers a useful
tool to investigate the molecular pathways and drugs to improve
functional outcome after cerebral ischemia in preclinical stud-
ies. Over the past 10 years, suitable models for stroke in aged rats
have been established. All are based on the middle cerebral artery
occlusion (MCAO) (Buga et al., 2013).
To date, all monotherapeutic attempts to prevent or lessen
brain damage following stroke have failed. In view of our findings
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that stroke impacts a wide range of systems in an age-dependent
manner, from CNS physiology to CNS regeneration and plasticity
(Popa-Wagner et al., 2011; Buga et al., 2013, 2014), the failure of
therapies aimed at only a single target system is perhaps inevitable.
We hypothesize that a multi-stage and multimodal treatment in
aged animals may be more likely to produce positive results.
The endogenous approach [granulocyte colony-stimulating
factor (G-CSF)-induced stem cell mobilization] has been shown
to enhance post-stroke recovery and to reduce infarct volumes
even when treatment was delayed for several days after stroke
onset (Schneider et al., 2005; Lu and Xiao, 2006; Schäbitz and
Schneider, 2007). G-CSF treatment was therefore translated into
human stroke where the safety of several doses could be estab-
lished (Schäbitz et al., 2008; England et al., 2012; Ringelstein et al.,
2013).
Cellular therapy can enhance the endogenous restorative mech-
anisms of the injured brain by supporting processes of neovascu-
larization, neurogenesis, and neural reorganization (Chen et al.,
2005; Crigler et al., 2006; Hayase et al., 2009; Bao et al., 2011; Lim
et al., 2011; Hsieh et al., 2013). Several studies showed that graft-
ing of BM MSCs in the peripheral circulation improved functional
neurological outcome and reduced infarct volume (Honmou et al.,
2012). Most of these studies used BM MSCs but feasibility and
safety in clinical trials was also shown for the bone marrow
mononuclear cells (BM MNCs) (Hermann and Chopp, 2012;
Moniche et al., 2012). A conclusive result on optimal timing and
dosing is, however, still missing.
In a previous work, we have shown that application of G-
CSF shortly after stroke in aged rats increases neurogenesis and
improves some of the behavioral indices (Popa-Wagner et al.,
2010). Therefore, we reasoned that the efficiency of the bone
marrow-derived-cell therapy may be increased by simultaneous
application of G-CSF. In particular, we tested the hypothesis that
grafting of pre-differentiated mesenchymal cells in G-CSF-treated
animals improves long-term functional outcome in aged rodents.
MATERIALS AND METHODS
ANIMALS AND EXPERIMENTAL DESIGN
The subjects of these experiments were aged male Sprague-Dawley
rats (N = 80; 18–20 months of age; 520–600 g) kept under stan-
dard laboratory conditions with free access to food and water. The
numbers reported in the results refer to the number of animals that
survived the surgery and completed the 8-week testing period. All
experiments were approved by the Animal Experimentation Ethics
Board of the State of Mecklenburg-Vorpommern as meeting the
ethical requirements of the German National Act on the Use of
Experimental Animals (approval no LALLF M-V/TSD/7221.3-1.1-
040/10) and by the Institutional Animal Care and Use Committee
of the Medical University of Craiova.
RANDOMIZATION
A scientist was in charge of randomization by (i) group assign-
ment, (ii) surgery assignment; and (iii) treatment assignment.
BEHAVIORAL TESTING
To evaluate changes in neurological function associated with
ischemia, the rats were subjected to a variety of somatosensory,
motor, learning, and memory tests before and after surgery. All
testing was performed from 9 to 11 a.m. Results obtained before
surgery were used to define 100% functionality for each animal
on each test, and functional recovery was expressed as percent
recovery relative to the pre-surgery baseline.
ROTATING POLE
The rotating pole task assesses coordination and sensorimotor
function in the MCAO model. Each rat was tested for its ability to
cross a rotating (6 rpm) horizontal rod. The score assessment was
done as previously described by our group (Buchhold et al., 2007).
Briefly, the time taken for the rat to traverse the rotating cylinder
and join a group of rats visible at the finish line was measured. The
score assessment was twofold: (i) time (seconds) required to tra-
verse the rotating cylinder and (ii) the score as follows: 0 – rat falls
immediately (onto a soft surface); 1 – rat does not walk forward,
but stays on the rotarod; 2 – rat walks, but falls before reaching
the goal; 3 – rat traverses the rod successfully, but the limbs are
used asymmetrically; 4 – the left hindlimb is used less than 50% of
the time taken to traverse the rod; 5 – the rat successfully traverses
the rod, but with some difficulties; 6 – no mistakes, symmetric
movements.
ASYMMETRIC SENSORIMOTOR DEFICIT: ADHESIVE TAPE REMOVAL
TEST
We assessed the asymmetry of sensorimotor deficit of the forelimbs
induced by unilateral MCAO by the adhesive tape removal test. In
short, sticky patches were applied on the distal hairless parts of the
forelimbs and the removal time from both limbs was measured.
Three trials were done separately for each limb and the means of
the values were noted. If the animal did not remove the tape within
180 s, the timer was stopped. Results are given as time needed to
remove the adhesive tape from one forelimb divided by the sum
of time needed to remove it from both forelimbs (Popa-Wagner
et al., 2010).
MORRIS WATER MAZE
The Morris water maze task was used to assess spatial learning and
memory. One week before surgery, aged rats were trained to find
a submerged platform in a large (180 cm-diameter) pool filled to
within 20 cm of the upper edge with water maintained at 26°C.
The pool was divided into four compass quadrants (north, south,
east, and west). Several visual stimuli were placed in each of the
four quadrants. For the acquisition of spatial learning, each ani-
mal underwent a block of four trials per day for 7 days. Before the
first trial, the rat was placed on the hidden platform for 30 s by the
investigator. Each trial consisted of placing the rat in the water at
one of the randomly selected four starting locations around the
pool perimeter. Each rat was allowed a maximum of 60 s to find
the hidden platform and remain on it for 30 s. If a rat failed to find
the platform within 60 s, the rat was placed on the platform for 30 s
by the investigator. The time and distance required to find the hid-
den platform during these four acquisition trials were averaged
(Tottori et al., 2002). The swim path was recorded by an image
analysis system (VideoMot2, TSE, Bad Homburg, Germany) that
computed path length and percentage of time spent in each of
the four quadrants. Functional restoration of spatial learning and
Frontiers in Aging Neuroscience www.frontiersin.org June 2014 | Volume 6 | Article 130 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balseanu et al. Stroke therapy in aged rodents
memory was estimated by weekly testing after MCAO and in total
for 8 weeks.
PREPARATION OF RAT BONE MARROW-DERIVED MESENCHYMAL
CELLS (rBM-MSC)
Bone marrow was collected from 40 Sprague-Dawley (5 weeks old;
Harlan-Winkelmann,Borchen,Germany). Both femurs were asep-
tically removed and placed in alpha-MEM (Biochrom, Germany)
supplemented with 20% fetal bovine serum (FBS, Biochrom, Ger-
many), 1% penicillin/streptomycin (Biochrom, Germany), and
2 mM HEPES (Biochrom, Germany), to which we refer as stan-
dard medium. The bone marrow was flushed out with 5 ml
standard medium using a 10 ml-syringe and a 23-gage needle
and the BM MSC was isolated and cryopreserved as previously
described (Sauerzweig et al., 2009). The cells were counted using a
Neubauer-hemocytometer and cultured with a density of 2× 106
whole marrow cells per square centimeter in standard medium
with 37°C, 5% CO2, and 92% relative humidity (RH). After
3 days, non-adherent cells were removed by flushing with 10 ml
PBS 0.1 M and the standard medium was replaced. The attached
cells were cultured until 80% of confluence was reached. After
trypsinization, cells were dissolved in standard medium supple-
mented with 10% DMSO (Sigma-Aldrich, Germany) and appor-
tioned for cryo-preservation. Immunophenotyping of rBM-MSCs
was performed with antibodies against rat antigens CD29, CD45,
and CD90.
PREPARATION OF HUMAN BMMSCs (hBMMSCs)
Mesenchymal stem cells (MSCs) harvested and cultured from nor-
mal human bone marrow were purchased from Lonza Research
(Cologne, Germany) and cultivated according to manufacturer’s
protocol under the same conditions as rat cells. The phenotypes of
hBM MSCs used in this study were positive for CD105 and CD166.
Cells tested negative for CD14, CD34, and CD45. Cells were tested
for purity by flow cytometry and for their ability to differentiate
into osteogenic, chondrogenic, and adipogenic lineages by Lonza.
INDUCTION OF STROKE
Eighteen hours prior to surgery, rats were deprived of food to min-
imize variability in ischemic damage that can result from varying
plasma glucose levels. Water remained available at all times. In all
cases, surgery was performed between 9:00 and 13:00 hours.
Cerebral infarction was induced by transcranial interruption of
blood flow by transiently lifting the middle cerebral artery (MCA)
with a tungsten hook as previously described (Popa-Wagner et al.,
2010). Throughout surgery, anesthesia was maintained by spon-
taneous inhalation of 1–1.5% halothane in a mixture of 75%
nitrous oxide and 25% oxygen. Body temperature was maintained
at 37°C by a Homeothermic Blanket System (Harvard Appara-
tus). The local changes in blood flow were monitored using a
laser Doppler device (Perimed, Stockholm, Sweden). A decrease
in the laser Doppler signal to <20% of control values was con-
sidered to indicate successful MCA occlusion. After 90 min, the
tungsten hook was released and the common carotid arteries were
re-opened. Surgery was performed under antiseptic conditions to
minimize the risk of infection. Subsequent to survival times of
56 days, the rats were deeply anesthetized with 2.5% halothane in
75% nitrous oxide and 25% oxygen, and perfused with neutral
buffered saline followed by buffered 4% freshly depolymerized
paraformaldehyde. The brain was removed, post-fixed in 4%
buffered paraformaldehyde for 24 h, cryoprotected in 15% glyc-
erol prepared in 10 mmol/l phosphate buffered saline, flash-frozen
in isopentane, and stored at−70°C until sectioning.
TREATMENTS
Animals were randomly assigned to three groups as follows: (i)
G-CSF group (N = 20) received daily injections of 50µg/kg BW
and in total for 28 days; (ii) G-CSF+BM MSCs (N = 20) group
received daily injections of G-CSF at 50µg/kg BW and in total
for 28 days and a single dose of BM MSCs (1× 106/kg BW)
given intravenously; and (iii) control group (N = 20) was given
daily the vehicle (5% glucose) for 28 days. Combination treat-
ment was done at 6 h post-stroke (Figure 1, upper panel). To
investigate the localization of injected cells, a separate group of
aged animals was injected with mesenchymal cells of human ori-
gin (hBM-MSCs). Although hBM-MSCs are poorly immunogenic
(Chamberlain et al., 2007) and the rats survived just 4 days after
administration, to prevent graft rejection the animals were given
cyclosporine A (s.c., Sandimmun, Novartis, 10 mg/kg) diluted in
Chremophor EL (Sigma).
BrdU LABELING
To label newly generated cells, rats were given bromodeoxyuri-
dine (BrdU; 50 mg/kg body weight, i.p.; Sigma), daily in the first
week post-stroke, and every other day in the following weeks
post-stroke, for a total period of 4 weeks.
MAGNETIC RESONANCE IMAGING
Magnetic resonance imaging (MRI) was used to visualize the
infarct volume for both groups at day 3 and at day 48 after stroke.
MRI measurements were performed on a 7-T Bruker ClinScan
magnet with a 20 cm inner bore, capable of 290 mT/m in 250µs
(Bruker BioSpin MRI, Ettlingen, Germany). Images were received
by a 2× 2 phased array RF coil, designed specifically for rat brain
studies that was placed directly on the skull. The animals were
anesthetized during imaging to minimize discomfort. Respiratory
rate was monitored, and isoflurane concentrations were varied
between 1.5 and 2.0% to keep the respiratory rate between 35 and
45/min. After positioning the animal’s head, quantitative T2 mea-
surements were performed with a multislice spin-echo sequence
with 25 slices of 0.7 mm thickness and a matrix size 640× 640
pixels, a repetition time (TR) of 4330 ms, and an echo time (TE)
of 45 ms.
LESION MEASUREMENT USING MIPAV SOFTWARE
T2WI lesion volumes were determined using the image process-
ing software Medical Image Processing, Analysis and Visualization
(MIPAV, version 3.0, National Institutes of Health, Bethesda, MD,
USA). After optimal adjustment of contrast, the edge of the lesion
was traced manually on each of the 25 coronal slices, which com-
pletely covered the MCA territory in all animals. The areas of
hyperintensity were then summed and multiplied by the slice
thickness to calculate lesion volumes.
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FIGURE 1 | Experimental design and time course of cutaneous
sensitivity and sensorimotor integration recovery after stroke therapy.
(A) Schematic overview of the experimental design. (B,C)Time course of
cutaneous sensitivity and sensorimotor integration recovery after stroke
therapy by the adhesive tape removal test. By day 3, post-stroke animals
started recuperation and reached significant recovery of function by day 14
in the G-CSF group [(B), filled red squares] as compared to the control group
[(B), filled black circles]. The combination of G-CSF and BM MSC showed no
significant improvement of recuperation of sensorimotor function [(C), filled
green squares] vs controls [(C), filled black circles]. (D,E) Functional
recovery on the rotating beam. Control rats began improvement and
recovered to 47% by day 56 [(D), (E) filled black circles]. Of the treated
groups, best recovery of the bilateral sensorimotor coordination was shown
in G-CSF alone that reached 72% of the pre-surgery value [(D), red squares]
followed by G-CSF+BM MSC [58%; (E), blue squares]. Data are given as
mean±SEM.
DETERMINATION OF INFARCT VOLUME BY IMMUNOHISTOSTAINING
To assess the size of the infarct induced by focal ischemia, we
introduced several years ago NeuN immunostaining (Badan et al.,
2003). Every 20th free-floating section of 25µm was immunos-
tained for NeuN to cover the entire infarcted volume, which
was then calculated as the sum of the partial areas using the
MicroBrightField (Colchester,VT, USA) system. Integration of the
resulting partial volumes (partial areas× no. of sections× section
thickness× section intervals) yielded the total volume of the
ipsilateral hemisphere along with the total volume of the infarct.
IMMUNOFLUORESCENCE
Cryostat, free-floating sections of 25µm were fixed in 4%
paraformaldehyde for 15 min and then washed extensively with
PBS and processed using an automatic staining machine for
floating sections Tingomat 5011. After incubation in 50%
formamide/2× SSC for 2 h at 60°C, sections were washed again,
first in 2× SSC and then in 10× PBS. After denaturization in 2 N
1http://www.tingomat.com
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HCL at 37°C for 40 min, sections were made neutral by adding
0.1 M borate buffer (pH 8.5). Thereafter, sections were incubated
with guinea pig anti-doublecortin (DCX; Millipore, Germany)
overnight at 4°C followed by secondary biotinylated antibod-
ies (Dianova, Hamburg, Germany) and visualized with strepta-
vidin Alexa 488 (Life Technologies, Karslruhe, Germany). Finally,
sections were incubated with rat anti-BrdU antibody (1:2000, AbD
Serotec, Puchheim, Germany). BrdU-positive cells were visualized
by incubating with Cy3-conjugated donkey anti-rat IgG (H+ L)
(1:3000). For phenotyping in the periinfarcted area and beyond the
fibrotic scar, sections were triple-immunolabeled with rabbit anti-
laminin-specific antibodies (1:5000, Sigma, Munich), mouse anti-
NeuN antibodies (1:500, Millipore, Germany), mouse anti-RECA
(1:1000, Millipore, Germany), and rat anti-BrdU-specific anti-
bodies (1:3000; Serotec, UK). The antigen–antibody complexes
were visualized with donkey anti-mouse Cy3-conjugated anti-
bodies (1:2000), donkey anti-rabbit Cy2-conjugated antibodies
(1:3000), and donkey anti-rat Cy5-conjugated antibodies (1:2000),
respectively.
For phenotyping of transplanted cells, the tissue was incubated
with a rabbit anti-mouse NeuN (1:1000, Novus Biologicals, UK)
or mouse anti-human CD166 (1:1000,antibodies-on-line,Aachen,
Germany) or mouse anti-human nuclei (ABIN361360 antibodies-
on-line,Aachen,Germany) or mouse anti-human CD105 antibod-
ies at 4°C overnight. At the next day, sections were rinsed with PBS
and incubated with Alexa Fluor® 568 goat anti-rabbit IgG or Alexa
Fluor® 594 goat anti-mouse IgG for CD105. Finally, the signal
was amplified utilizing an anti-mouse polymer-based secondary
detection system (Histofine polymer-HRP, Nichirei, Japan) diluted
1:10 in PBS containing 1% normal goat serum and 0.3% Tween
20. After washing in PBS, sections were stained with tyramide-
FITC. After final rinsing, sections were brought to Superfrost Plus
slides and mounted using PVA/DABCO-containing medium. To
visualize nuclei, some sections were counterstained with DAPI.
QUANTITATION OF MICROVASCULAR DENSITY
Microvascular density was quantitated using the “hot spot” analy-
sis covering 30% of the infarcted area. Briefly, hot-spots, i.e.,
regions with a high density of CD105-positive microvessels in
humans and CD31-capillaries in rats, were identified using a 40×
objective and were then counted using 20× objective, correspond-
ing to a microscopic field of 0.7386 mm2. Counting was done
by two independent observers and the results are expressed as
means± SD (Buga et al., 2014).
MICROSCOPY
For light microscopy, a Nikon Eclipse (Nikon, Duesseldorf, Ger-
many) was used. Confocal microscopy images were acquired using
a Zeiss LSM710 laser-scanning confocal system with spectral
detection capabilities, and Zen 2010 software version 6.0 (Carl
Zeiss Microscopy GmbH, Jena, Germany) was used for image
acquisition and analysis. Excitation light was provided by 488,
543, and 634 nm laser lines; fluorescence emission was detected
at 500–530 nm for FITC (green), 550–600 nm for rhodamin (red)
and 650–710 nm for Cy5 (blue) in separate tracks, using a confo-
cal aperture of 1 Airy unit. Some of the images were acquired as
z-stacks and 3D reconstruction was performed.
STATISTICAL ANALYSIS
The main effects of treatment and time as well as interactions of
the two factors, on recovery, were evaluated using a mixed-model
analysis of variance (MANOVA) for each measure, with treat-
ment as between-subjects variables and time as a within-subject
variable. The non-parametric data analysis was conducted using
the Kruskal–Wallis test that is designed for multiple independent
measures followed by a Bonferroni correction for alpha errors
(SPSS Inc., Chicago, IL, USA). A p value of <0.05 was considered
to be statistically significant. Water maze analysis was done using
the Wilcoxon rank sum test.
RESULTS
GENERAL OBSERVATIONS
To facilitate feeding in aged animals during the first 3 days post-
stroke, we fed them with moistened, soft pellets. Following infarc-
tion, all rats had diminished performance on the first 3 days
post-surgery, which was at least partially attributable to the surgi-
cal procedure itself. The mortality rate was almost identical, 10%
for each group. All the above mentioned animals died between day
3 and day 10 post-stroke.
THE EFFECT OF G-CSF AND ITS COMBINATION WITH BMMSCs ON
FUNCTIONAL RECOVERY IN POST-STROKE AGED RATS
The adhesive tape removal test probes for differences between fore-
limbs in cutaneous sensitivity and sensorimotor integration after
stroke. As compared to pre-operative, trained animals, rMCAo
animals demonstrated a marked difference in post-operative per-
formance for the left (affected) forelimb. By day 3, post-stroke
animals started recuperation and reached significant recovery
of function by day 14 in the G-CSF group only (Figure 1B,
filled red squares). The combination between G-CSF and BM
MSC showed no additional or showed a similar although non-
significant trend improvement of recuperation of sensorimotor
function (Figure 1C, filled green squares).
After an abrupt decline in performance on the rotarod on day 3
post-stroke, control rats began improvement and recovered to 47%
by day 56 (Figure 1D, filled black circles). Of the treated groups,
the best recovery was shown by group treated with G-CSF alone
that reached 72% of the pre-surgery value (baseline) (Figure 1D,
red squares) followed by the group treated with G-CSF+BM MSC
that reached 58% of the pre-stroke value (Figure 1E, blue squares).
Representative swim paths are shown in Figures 2A–C and
included the start of training (−7d), the pre-surgery path pat-
tern (0d), first testing after stroke (+7d), and the final testing
(+56d). Over the pre-stroke training period of 7 days, rats learned
to locate and climb onto the hidden platform and performance
improved significantly during this time. In all groups, the path
became shorter as the training sessions progressed (Figures 2A–
C). Because of the skull injury, we avoided testing the animals in
the first week post-stroke.
As previously shown, aged rats need more time to recover
behaviorally after stroke than young animals (Lindner, 1997; Tot-
tori et al., 2002; Lindner et al., 2003; Buchhold et al., 2007).
Consequently, the path length required to reach the platform in
the third quadrant reached a maximum by day 7 post-stroke. After
7 days, the animals began recovering in this test. The best recovery
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FIGURE 2 |Time course of post-stroke recovery of learning and (spatial)
memory by water maze. Representative swim paths are shown in (A–C)
and included the start of training (−7d), the pre-surgery path pattern (0d), first
testing after stroke (+7d), and the final testing (+56d). The best recovery was
seen for the G-CSF group that showed significant improvement of spatial
reference-memory between days 21 and 49 in the second quadrant [(D);
p=0.05]. However, in the third quadrant, the performance was temporarily
improved between days 14 and 28 in the group treated with G-CSF+BM
MSC as compared to the control group [(E); p=0.019]. Data are given as
mean±SEM.
was seen for the G-CSF group that showed significant improve-
ment of spatial reference-memory between days 21 and 49 in the
second quadrant (Figure 2D). However, in the third quadrant, the
performance was temporarily improved between days 14 and 28
in the group treated with G-CSF+BM MSC as compared to the
control group (Figure 2E).
THE EFFECT OF CELL THERAPY ON THE INFARCT VOLUME
Representative MRI data for the two rats closest to the mean
for each group are shown in Figures 3A–F. Cortical lesion and
brain edema at day 3 post-stroke, as defined by the region of
T2 hyperintensity, was not significantly reduced by any treat-
ment (Figures 3A–C). The G-CSF group showed, however, less
edema as compared with the combination treatments or controls
(Figure 3J, red bar). The second MRI done at day 48 post-stroke
revealed much smaller infarcts suggesting that brain edema has
had a large contribution to the T2 hyperintensity in aged animals
(Figures 3D–F).
Immunohistochemical staining of the infarct area at day 56
using an anti-NeuN antibody (Figures 3G–I) showed that the
infarct volumes were largely similar to those measured by MRI
at day 48, indicating that the infarct volume had stabilized by
day 48. Consequently, the infarct volume as measured by MRI
(Figure 3K) or immunohistochemistry (Figure 3L) was not
significantly different between the groups at day 48 post-stroke.
LOCALIZATION OF HUMAN BMMSCs BY PHENOTYPING
In the ipsilateral hemisphere, the injected human BM MSCs were
detected in the corpus callosum as shown for CD166-positive cells
(Figure 4A, arrows) and CD105-positive cells (Figure 4F, arrows).
In our model the cell probably entered the injured brain via the
lateral ventricle as shown by the CD166-positive cells (Figure 4B).
A fraction (about 1%) of the injected CD166- and CD105-positive
cells reached the infarcted area (Figures 4C,E, arrows) where they
were intermingled with surviving or degenerating neuronal nuclei
(Figure 4C, arrowheads). Noteworthy was also the presence of
immunopositivity for human nuclei (Figure 4D, arrows) that were
dispersed between the rat nuclei in the infarcted area (Figure 4D,
arrowheads).
THE COMBINED TREATMENT DID NOT ENHANCE NEUROGENESIS IN
THE SUBVENTRICULAR ZONE
Next, we investigated the presence of the early neuronal marker
doublecortin by immunofluorescence in the lateral ventricle
region. To this end, the proliferating cells were labeled by inject-
ing animals with BrdU. To our surprise, at day 56 post-stroke
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FIGURE 3 | Edema and stroke volumes by MRI and NeuN
immunohistochemistry. (A–C) Perilesional brain edema at day 3
post-stroke, as defined by the region of T2 hyperintensity (A) was not
significantly reduced by any treatment (J). (D–F)The second MRI
done at day 48 (B) post-stroke revealed much smaller infarcts.
(G–I) By immunohistochemistry at day 58, the infarct volumes for
controls (G), G-CSF alone (H), and combination treatment (I) were
largely similar to those measured by MRI at day 48. The infarct
volume after 7–8 weeks post-stroke was not significantly different
among the groups (K,L).
none of the DCX+ cells in the SVZ of control animals co-
localized with BrdU-labeled nuclei. Instead, the BrdU-positive
nuclei were distributed mainly in the “pinwheel” architecture of
the ventricular epithelium (Liebner et al., 2008; Gajera et al.,
2010) (Figure 5A). The DCX+ cells occupied an adjacent, dis-
tinct position (Figure 5A, arrows). Some of the DCX+ migrated
away from the ventricular wall (Figure 5B). In agreement with
the previous results, we noted vigorous neurogenesis with many
DCX+ (arrows) co-localizing with BrdU nuclei in the G-CSF-
treated animals (Figure 5C; arrowheads) and animals treated with
G-CSF+BM MSC (Figure 5D, arrows).
INCREASED MICROVASCULAR DENSITY IN THE G-CSF+BMMSC
GROUP
In regions adjacent to the infarct scar, we found numerous
BrdU+ nuclei in the endothelium of newly formed blood ves-
sels in the formerly infarct core (Figure 5E, green). The bor-
der to the healthy brain region was abruptly demarcated to the
left by NeuN-positive nuclei (Figure 5E, NeuN shown in red).
Beyond the formerly infarct core, we noted vigorous sprouting
angiogenesis as evidenced by RECA/BrdU double positive blood
vessels (Figure 5F, violet) as well as numerous BrdU+ nuclei in the
newly formed endothelium (Figure 5F, blue) and reconstruction
of the basal lamina (Figure 5F, green) during the resolution phase
of angiogenesis. By number of laminin/BrdU co-localizations, the
density of the newly formed blood vessels was significantly higher
(threefold,p= 0.01) in the brains of animals treated with the com-
bination G-CSF+BM MSC as compared to controls and G-CSF
alone (Figure 5G).
DISCUSSION
The aged post-stroke brain microenvironment is refractory to
regeneration (Conover and Shook, 2011; Popa-Wagner et al.,
2011). Bone marrow-derived cell therapy includes the grafting
of stem cells as well as the delayed induction of endogenous stem
cell mobilization and homing by the stem cell mobilizer G-CSF
(Schäbitz and Schneider, 2007; Schäbitz et al., 2008). In this study,
we tested the hypothesis that such a combination is superior to
G-CSF alone. We found that the aged brain environment is permis-
sive for the migration of human BM MSC toward the lesion site.
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FIGURE 4 | Phenotyping of human BMSCs. In the ipsilateral
hemisphere, the injected human BMSCs were localized in the corpus
callosum as shown for CD166-positive cells [(A), arrows] and
CD105-positive cells [(F), arrows]. In our model, the cells most likely
entered the injured brain via the lateral ventricle as shown by the
CD166-positive cells (B). A fraction (about 1%) of the injected CD166-
and CD105-positive cells reached the infarcted area [(C,E), arrows]
where they were intermingled with surviving or degenerating neuronal
nuclei [(C), arrowheads]. Noteworthy was also the presence of
immunopositivity for human nuclei [(D), arrows] that were dispersed
between the rat nuclei in the infarcted area [(D), arrowheads]. Cc, corpus
callosum; IC, infarct core; LV, lateral ventricle; PI, periinfract.
Further, the combination therapy increased neurogenesis in the
subventricular zone and improved significantly recuperation and
microvessel density in the formerly infarct core and beyond. How-
ever, neither G-CSF nor the combination was efficient in reducing
the mortality rate and the infarct volume. These findings are con-
sistent with previous reports using cellular post-stroke therapies
(Chen et al., 2000, 2004; Zhao et al., 2002; Popa-Wagner et al.,
2010) or human adult bone marrow-derived somatic cells (Braun
et al., 2012).
Different routes of MSC administration have been used to treat
damaged ischemic brain tissue. Of these, the intravenous infusion
of BM MSCs might be a feasible and safe mode for treatment of
stroke patients (Chen et al., 2003). Some other studies have shown
that, on the contrary, intrathecal delivery by lumbar puncture may
be a more efficient approach for the BM MSCs treatment of stroke
(Lim et al., 2011).
Mesenchymal stem cells exhibit intrinsic homing properties to
sites of injury, inflammation, and hypoxia (Orlic et al., 2001; Hof-
stetter et al., 2002; Mahmood et al., 2003; Spaeth et al., 2008) that
can be used for targeted delivery of therapeutic factors. In a mouse
model of glioblastoma, a large number of cells migrated toward
the tumor along the corpus callosum (Menon et al., 2009). Our
study shows that the aged rat brain environment still support this
migratory pathway in the ischemic brain as suggested by the pres-
ence of several marker of human MSCs, CD166, and CD105 in the
corpus callosum and periinfarcted area.
Cerebral ischemia can cause both physical disability and pro-
longed spatial memory disturbance in rodents, a phenomenon
aggravated by advanced age (Buchhold et al., 2007; DiNapoli et al.,
2008; Bingham et al., 2012). Improved functional recovery includ-
ing performance of a skilled forelimb reaching task following
transplantation of MSC of human or rat origin (Hayase et al.,
2009; Bao et al., 2011; Jiang et al., 2012) or cognitive restoration
estimated by Morris water maze following transplantation of MSC
rat origin has also been reported (Pavlichenko et al., 2008).
Intravenous transplantation of MSCs led to motor function
improvement as assessed by fMRI (Suzuki et al., 2013). In a pre-
vious study, we have shown that post-stroke G-CSF treatment
of aged animals improved survival and had a beneficial effect
on functional outcome in somatosensory, motor, learning, and
memory tests. However, this beneficial effect was not lasting but
overlapped with the G-CSF treatment period (Popa-Wagner et al.,
2010). In the present study, the combination of G-CSF and BM
MSC in aged rats showed, surprisingly, no additional improvement
in recuperation of the sensory function (adhesive tape) although
recuperation of more complex motor (rotating pole) and spatial
reference-memory tasks was improved both by G-CSF and the
combination. Our findings are in agreement with earlier stud-
ies showing no improvement of clinical symptoms after hMSC
transplantation in a mouse model of stroke (Steiner et al., 2012).
Stroke in young animals promotes cell proliferation in the SVZ
and increases the number of immature neurons (Arvidsson et al.,
2002; Parent et al., 2002). Previously, we have shown that G-CSF
has increased neurogenesis by day 28 in the post-stroke aged brain
(Popa-Wagner et al., 2010). In the present study, the animals sur-
vived for 60 days. At day 56, neurogenesis still persisted in the
ipsilateral SVZ of the aged post-stroke control brains. In control
brains, the DCX+ cells occupied an adjacent, distinct position
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FIGURE 5 | Post-stroke neurogenesis and angiogenesis. At 8 weeks
post-stroke, none of the DCX+ cells in the SVZ of control animals co-localized
with BrdU-labeled nuclei. Instead, the BrdU-positive nuclei were distributed
mainly in the “pinwheel” architecture of the ventricular epithelium (A). The
DCX+ cells occupied an adjacent, distinct position [(A), arrows]. Some of the
DCX+ migrated away from the ventricular wall (B). We noted vigorous
neurogenesis with many DCX+ (arrows) co-localizing with BrdU nuclei in the
G-CSF-treated animals [(C); arrowheads] and animals treated with
G-CSF+BM MSC [(D), arrows]. (E–G) Post-stroke angiogenesis. In regions
adjacent to the infarct scar, we found numerous BrdU+ nuclei in the
endothelium of newly formed blood vessels in the formerly infarct core [(E),
green]. The border to the healthy brain region was abruptly demarcated to the
left by NeuN-positive nuclei [(E), red]. Beyond the formerly infarct core, we
noted vigorous sprouting angiogenesis as evidenced by RECA/BrdU double
positive blood vessels [(F), violet] as well as numerous BrdU+ nuclei in the
newly formed endothelium [(F), blue] and reconstruction of the basal lamina
[(F), green] during the resolution phase of angiogenesis. By number of
laminin/BrdU co-localizations, the density of the newly formed blood vessels
was significantly higher (threefold, p=0.01) in the brains of animals treated
with the combination G-CSF+BM MSC as compared to controls and G-CSF
alone (G). Cc, corpus callosum; IC, infarct core; IR, islet of regeneration; LV,
lateral ventricle; PI, periinfract.
while some of the DCX+migrated away from the ventricular wall.
In agreement with previous results, we noted vigorous neurogen-
esis and many DCX+ co-localized with BrdU nuclei in the SVZ of
G-CSF-treated animals.
Reports on the differentiation of transplanted cells yielded con-
flicting results. Earlier studies have shown that MSCs injected
into the lateral ventricle of neonatal mice persistently engraft
and migrate throughout the brain and adopt an astrocyte-,
oligodendrocyte- (Zhao et al., 2002; Lu et al., 2008), or endothelial
cell-like phenotypes (ECs) some of them being incorporated into
newly formed brain vessels (Hess et al., 2002; Zhang and Harder,
2002; Foteinos et al., 2008). Occasionally, a neuronal phenotype
has been reported in vivo (Kopen et al., 1999; Brazelton et al.,
2000; Priller et al., 2001) at the site of injury (Ankeny et al., 2004;
Lu et al., 2005) and in vitro (Deng et al., 2006). Committed neural
progenitor cells, NS-MSCs, produced in vitro from rat and human
MSCs, differentiated into neuronal cells after transplantation
and became immunoreactive to various neurotransmitter-related
markers within the host tissue.
In our model, the MSC reached the periinfarcted region after
4 days. However, 56 days after the administration of BM MSCs,
the proliferation marker BrdU had been incorporated preferen-
tially in the “pinwheel” architecture of the ventricular epithelium
(Liebner et al., 2008; Gajera et al., 2010) and blood vessel in the
formerly infarct core while the DCX+ cells occupied an adjacent,
distinct position in the SVZ, and were not detectable at all in the
lesioned area. Since BrdU was administered for the first 14 days
after stroke, we concluded that at 2 months post-stroke DCX+
cells with BrdU nuclei did not survive strongly suggesting that the
early neuronal progenitors did not survive in the hostile environ-
ment of the post-stroke aged brain. Instead, in animals treated with
the combination of G-CSF and BM MSCs, we noted an increased
number of newly formed blood vessels in the formerly infarct core
and the region beyond it which we dubbed the “islet of regenera-
tion” (Buga et al., 2014). These results strongly suggest that the BM
MSC promoted angiogenesis rather neurogenesis in the lesioned
area (Bronckaers et al., 2014). Indeed, previous studies have shown
that delayed intracerebral injection of h BM MSCs modified the
cerebral microvasculature after transient ischemia (Moisan et al.,
2012) and improved the cerebral blood flow (CBF) (Jiang et al.,
2012).
The current understanding of mechanisms underlying stroke
treatment with bone marrow-derived cells is that homing of cells
into the infarcted brain may cause trophic support and hereby
enhanced post-stroke recovery. Transplanted NSCs may promote
recovery also without differentiating to neurons and even without
long-term survival through several other mechanisms, e.g., neu-
rogenesis (Tfilin et al., 2010), modulation of inflammation (Lee
et al., 2008; Horie et al., 2011), neuroprotection (Bacigaluppi et al.,
2009), and stimulation of angiogenesis (Bronckaers et al., 2014)
and brain plasticity (Liu et al., 2008; Andres et al., 2011). Delayed
and persistent functional improvement induced by intracerebral
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NSC transplantation after stroke, without cell survival and tissue
replacement at 6 months after the insult, was recently documented
by electrophysiology, fMRI, and behavioral testing (Ramos-Cabrer
et al., 2010).
Therapeutic effects mediated by cell transplantation are likely
related to the secretion of growth factors and cytokines. Mecha-
nistically, studies done on young subjects using human umbilical
cord blood-derived MSCs or bone marrow-derived cell treatment
for stroke suggest that homing of cells into the infarcted brain
may cause trophic support for host neurons and hereby enhanced
post-stroke recovery. Indeed, MSCs enriched from adult human
umbilical cord and bone marrow have demonstrated therapeu-
tic efficacy for treatment of stroke in a rat model, presumably
by an increased expression of cytokines CXCL2 and CXCL5 and
growth factors BDNF, NT-3, FGF9, HBEGF, and VEGF in the
ischemic brain that was accompanied by reduction of the infarct
volume, increased neurogenesis, and improved neurological func-
tion (Chen et al., 2005; Crigler et al., 2006; Hayase et al., 2009;
Bao et al., 2011; Lim et al., 2011; Hsieh et al., 2013). However, our
combination therapy did not further enhanced neurogenesis in
the SVZ of aged animals.
Following stroke, angiogenesis, which is defined as formation of
microvessels from existing microvessels, is enhanced in the periin-
farcted region as compared to the contralateral unlesioned cortex
(Wang et al., 2005; Kilic et al., 2006; Zechariah et al., 2013). Angio-
genesis has multiple beneficial roles in the post-ischemic brain,
contributing to (i) the stabilization of brain hemodynamics, thus
preventing subsequent stroke events, (ii) the prevention of neu-
ronal degeneration via release of neurotrophic growth factors,
(iii) the removal of dead cells from the tissue by blood-derived
macrophages that find access to the ischemic lesion, and (iv)
the attraction of neural precursor cells that again release growth
factors (Slevin et al., 2006; Hermann and Zechariah, 2009).
The aged brain is particularly refractant to growth phenomena
after injuries. We and others have shown that potential mecha-
nisms for self-repair also operate in the post-ischemic aged brain.
The major factors involving the loss of regenerative capacity in
the aged brain are an age-related decrease in neurogenesis and an
increased inflammatory response to stroke that impairs regenera-
tion and migration of neuronal precursors toward the ischemic
lesion that is most evident in the aged brains (Popa-Wagner
et al., 2011). Although we found that the aged brain environ-
ment is permissive for the migration of BM MSCs, the number
of transplanted cells that have reached the periinfarcted region
was too small to have any relevance for tissue and functional
recovery.
CONCLUSION
Daily treatment of post-stroke aged rats with 50µg/kg G-CSF for
a longer time (28 days) led to a robust and consistent improve-
ment of several neurological functions. The combination therapy
of G-CSF and BM MSCs led to robust angiogenesis in the formerly
infarct core and beyond in the“islet of regeneration.”However, the
combination therapy with G-CSF and BM MSCs was not superior
to G-CSF alone, suggesting that one time cell administration is not
sufficient to improve tissue recovery after stroke in the aged brain
environment. Furthermore, G-CSF+BM MSCs may not impact
at all on the spatial reference-memory task or infarct volume and
therefore did not further improve the post-stroke recovery. We
conclude that in a real clinical practice involving older post-stroke
patients, successful regenerative therapies would have to be carried
out for a much longer time. The BM MSC therapy warrants further
investigation including repeated administrations of therapeutic
cells at several time points after stroke and using various com-
binations with G-CSF or other relevant growth factors/cytokines.
Another point that should be considered in future studies is a prob-
lem associated with autologous transplantation of BM MSCs in
elderly patients, in view of an age-related decrease in the functional
capacity of stem cells (reviewed by Moskalev et al., 2013).
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